Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Australia's lifesaving drug scheme review could require new evidence of real-life benefits

This article was originally published in Scrip

Executive Summary

Companies with drugs subsidized through the Australian Life Saving Drugs Programme (LSDP) may in future have to provide updated evidence of their products' real-life benefits or accept a price cut or delisting from the scheme, if proposals put forward in a government consultation document are taken forward.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC028406

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel